Neurocrine Biosciences, Inc.
NBIX
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
29 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$129.78
Price+1.57%
$2.00
1Y
Price
Market Cap
$13.025b
Large
Price/Earnings 3y Avg5y Avg
27.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+29.2%
EBITDA Margin+19.1%
Net Profit Margin+48.5%
Free Cash Flow Margin+29.2%
EBITDA Margin+19.1%
Net Profit Margin+48.5%
Free Cash Flow MarginRevenue
$2.861b
+21.5%
1y CAGR+24.3%
3y CAGR+26.1%
5y CAGREarnings
$478.600m
+40.2%
1y CAGR+46.2%
3y CAGR+52.7%
5y CAGREPS
$4.67
+41.6%
1y CAGR+44.4%
3y CAGR+50.7%
5y CAGRBook Value
$3.253b
$4.632b
Assets$1.378b
Liabilities$415.300m
DebtDebt to Assets
9.0%
0.6x
Debt to EBITDAFree Cash Flow
$748.700m
+34.4%
1y CAGR+33.5%
3y CAGR+34.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company